New Delhi, Aug. 9 -- Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to accelerate growth after reporting a strong first quarter, according to its top executive.

The company's revenue grew 18% year-on-year to Rs.2,458 crore, and Ebitda rose 36% on a like-for-like basis to Rs.645 crore in the quarter ended June. Its Ebitda margin expanded to 26% during the quarter.

"The growth this quarter has come from North America and Europe, in both the advanced markets. And primarily on our oncology franchise," chief executive officer Shreehas Tambe told Mint in an interview. Some of its key biosimilars in the oncology portfolio, such as Fulphila and Ogivri, have held market share ...